arimoclomol has been researched along with Gaucher Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aerts, JFMG; Bembi, B; Bornaes, C; Dardis, A; Fog, CK; Kirkegaard, T; Magnoni, R; Malini, E; Mehmedbasic, A; Peruzzo, P; Petersen, NHT; Solanko, LM; Zago, P | 1 |
| Hettinghouse, A; Liu, CJ | 1 |
2 other study(ies) available for arimoclomol and Gaucher Disease
| Article | Year |
|---|---|
The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase.
Topics: Cell Line; Endoplasmic Reticulum; Enzyme Activation; Fibroblasts; Gaucher Disease; Glucosylceramidase; Golgi Apparatus; Heat-Shock Proteins; Humans; Hydroxylamines; Lysosomes; Mutation; Neurons; Protein Processing, Post-Translational; Protein Refolding; Protein Transport | 2018 |
Brain-penetrant heat shock protein amplifier arimoclomol enhances GCase activity in in vitro Gaucher disease models.
Topics: Brain; Gaucher Disease; Glucosylceramidase; Heat-Shock Proteins; Humans; Hydroxylamines | 2018 |